Genelux Corp Appoints Jason Litten CMO
(RTTNews) - Genelux Corp. (GNLX), a clinical-stage immuno-oncology company, Friday announced that it has appointed Jason Litten as Chief Medical Officer, effective January 2.
Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones, the company said in a statement.
Litten is a veteran biopharmaceutical executive with over 20 years of experience spanning academia, pharmaceutical organizations, and biotech companies. Most recently he served as Chief Medical Officer at Chimeric Therapeutics, Ltd.
On Wednesday, GNLX shares closed at $4.36, up 0.46% on the Nasdaq.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.